Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Over 1M shares dumped at 0.027 ~ 0.03 during the past three days. I
bet next week the bottom 0.025 will be broken due to the asset sale
finished without any distribution to the shareholder! Who are those
very stupid buyers which bought the shares at 0.04 ~ 0.045?
The pos scam hit 0.027 today! Sell at bid ASAP before it breaks down the 52-week low or bottom 0.025. 317,410 shares dumped at 0.027 ~ 0.0291 this afternoon. Over 1M shares sold below 0.033.
Maybe thats why the piece of crap cant run, not all Q stocks run the way i see it the more assets the more likely it will run
http://stockcharts.com/h-sc/ui?s=bpurq&p=D&b=5&g=0&id=p11530901891
All the assets are gone now. BPURQ owns nothing besides the debts
and liabilities. The shares maybe canceled soon by the sick CEO.
What ever happened to the auction? did they sell off the companys assets or not
BPURQ is already bottomed out at $0.025 and will hit $0.04 again. I
am enjoying the huge profits right now. Please buy at asking only!
Yesterday the high was $0.04 which means 60% rally from $0.025. Why
today's high was only $0.035 which means 40% up. Could both $0.04 and $0.035 be the roof prices? Anyway the current ask is $0.0339.
Why the stock went down while the market rally? My cost is $0.029.
New 52-week low $0.025 was created yesterday! I am glad to own near
1M damn cheap shares (I bought at $0.025 ~ $0.035)! Anyway BPURQ is
already bottomed out at $0.025. $0.025 is the unbreakable bottom!!!
Biopure Corporation Receives Notice of Delisting from Nasdaq
* Press Release
* Source: Biopure Corporation
* On Friday July 17, 2009, 3:30 pm EDT
*
Buzz up! 0
* Print
*
Companies:
o Biopure corp.
CAMBRIDGE, Mass., July 17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced that it has received notice from The Nasdaq Stock Market, by letter dated July 17, 2009, that its common stock would be delisted from Nasdaq. The notice stated that because of concerns raised by the Company's filing for protection under Chapter 11 of the Bankruptcy Code, trading would be suspended at the opening of business on July 28, 2009.
The company does not intend to appeal this decision.
Biopure Corporation
Biopure Corporation develops and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues.
yeah, pretty much done here, luckily have only been watching...eom.
that was it... -50% today... BPUR announced today that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Massachusetts.
Golden Cross Alert
200ma crossed the 50ma. Usually long term bullish signal!
yes sir.... .50 looks very probable, and soon..GLTY.
fake early spike, but it looks like its capable of running, lets see more buyers break that .34 wall and its off to .50
Hi H6, Re: Biopure and NFLD..........
Considering the need for a reasonable "oxygen therapeutic" I certainly hope one will become available for common usage.
A couple of years ago some acquaintances of mine traveled to Africa to climb Mt. Kilimanjaro. The ascent went just fine, but one of them fell on the descent and was badly injured.
While he didn't require a transfusion, if he had, just think of the increased risk involved in the accident! Instead of head trauma and some extra broken bones, eventual facial reconstruction, impaired memory, etc. he'd have faced the possibility of blood born infection.
He, a pharmacist, happened to be there with two physicians. Even so, they all gave credit to a Dutch trauma nurse who happened to be climbing Mt. K. at the same time they were descending. She happened upon them just after the accidental fall had taken place. Her understanding of head trauma and how to do quick, on the spot emergency treatment, stabilized him enough that they could get him off the mountain (carrying him down by improvised stretcher) and get him to a hospital.
Talk about having all the stars align in one's favor!
The case for an oxygen carrying hydraulic support fluid that is stable and of reasonable shelf life would be terrific for emergency health work in civil emergencies as well as military activity.
Let's hope they or someone else eventually gets approved in the U.S. Right now Biopure's product, Hemopure, is approved for used in South Africa and the clinical experience gained there should eventually help with approval other places. Biopure's veterinary "oxygen therapeutic" - Oxygloben - has been approved for usage in the U.S. and abroad for about 10 years. They even helped devise a test for whether it had been infused for testing race horses (think of the KY Derby) and also for the Olympics, (think of a non steroidal, brief "enhancement").
Best regards, Tom
as posted before on this board, this news, now official, bodes very well for Biopure....again, kudos goes out to Tom Veale for the excellent DD......Posted by: Soapy Bubbles Date: Saturday, May 02, 2009 12:12:18 PM
In reply to: None Post # of 1110 [Send a link via email]
NFLD -- Bouncewatch -- Shares of Northfield Laboratories Inc. (NFLD) closed down 51% to 25 cents Friday after the company reported the Food and Drug Administration wouldn't grant final approval of its PolyHeme blood-substitute product.
maybe now is the time they can bring everything together, only time will tell...GLTY.
I have not been following them in some time, but they seem to have trouble doing just about anything.
It would be really great if this stuff could get on the market, for everybody, not just the investors.
they should have no trouble getting either, and about the $22 share price, well that's history.
hOW CAN THEY GET fda APPROVAL ?????
They cant even get ok for trials?
I remeber selling shares of this at $22.00
Hi Florida...if you look at post #261, you'll see an article related to Northfield labs. If is fact, Biopure's only real competitor is no longer viable, then Biopure will have this particular sector to themselves. If that wasn't enough, their 'Biopure' product appears poised for FDA approval, once the clinical trials are over. Yea, I'd say it looks promising!GLTY.
What a roller coaster ride last week for BPUR !!!! We got as low as .17, and rallied as high as .45, only to end the week at .22 Do any of you folks that know this company better than I do, have any ideas as to whether or not they can succeed ???? Florida
Hi H, I think I prefer "Rummer."
pirate@hiccough.arrg
sorry, meant runner.GLTA.
yea, you could call this one a quiet rummer, nice and steady climber, no fluff here.IMO.
This stock is moving like a SOB and not one post today???
Stock was down nearly %40 today and then shot up nearly %40 as a high.??????
Well folks, I certainly hope there's some meat to the hype on this pig.
Good news and upward move!
U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'RESUS' Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
* Monday March 23, 2009, 7:30 am EDT
CAMBRIDGE, Mass., March 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced today that the U.S. Naval Medical Research Center (NMRC) has submitted to the Food and Drug Administration (FDA) a revised investigational new drug (IND) application to conduct a clinical trial of the company's oxygen therapeutic Hemopure® [hemoglobin glutamer - 250 (bovine)] for the pre-hospital treatment of trauma patients. The study is entitled "Restore Effective Survival in Shock" (RESUS). The RESUS trial was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission was placed on clinical hold.
Related Quotes
Symbol Price Change
BPUR 0.38 +0.17
Under a research agreement with Biopure, the NMRC assumed primary responsibility, subject to funding, for designing, seeking FDA acceptance of and directing a trial for Hemopure's prehospital used in trauma patients with hemorrhagic shock. The NMRC has developed protocols for trials in civilian casualties in the United States and abroad (RESUS) as well as a trial proposed to be conducted in the field, called Operation RESUS (OP RESUS). To date, Congress has appropriated funds for the development of Hemopure for potential use in military and civilian trauma indications and to cover military administrative costs. This funding is being used for trial preparation and for preclinical studies of Hemopure in animal models, including those that mimic military trauma scenarios.
As previously reported, in June 2008 the NMRC submitted and subsequently withdrew an Op RESUS protocol for a Phase 2 clinical trial of Hemopure for resuscitation of operations casualties with severe traumatic hemorrhagic shock, when blood transfusion is not available. The proposed trial hypothesis is that for such casualties Hemopure will improve survival and other clinical parameters, and will be relatively safe and well tolerated, in comparison with "standard fluids." If the trial were permitted to proceed, subjects would sign an informed consent prospectively. The Op RESUS protocol was also revised, resubmitted and placed on clinical hold.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the Company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs.
LOL...Tom, you have to figure the Northfield news is likely the real catalyst here recently, thanks again for the excellent post.
Thanks Tom....that article definitely indicates that conclusion.
Their chief potential competitor, Northfield Labs, looks to be "terminal."
http://www.thestreet.com/_yahoo/story/10473728/1/northfield-polyheme-not-long-for-this-world.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
http://investorshub.advfn.com/boards/board.aspx?board_id=5355
TV
DOH!!! Missed it...argh.
Maybe tomorrow we can get close to today's HOD
Great day, just meant the wwweeeee was toast
I'm not sure what you mean by "toast," but up 75% in a day is fairly decent in my book...
Pretty big pull back, looks like it may be toast now
10 day average volume: 186,000
Today's volume (just past noon): 5.2 million
WOW!
off the races - here we go... on heavy volume...
weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee!
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
Wednesday December 17, 2008, 8:35 am EST
CAMBRIDGE, Mass., Dec. 17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced today that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company's oxygen therapeutic Hemopure® [hemoglobin glutamer - 250 (bovine)]. In the proposed trial Hemopure would be studied for use in the treatment of life-threatening anemia secondary to induction chemotherapy in patients with acute myeloid leukemia (AML) who refuse red blood cell transfusion.
As previously reported, the company met with the FDA in July 2008 to discuss an acceptable patient population for a new clinical trial. At that time the company proposed a trial in AML patients who will not accept blood transfusions and consequently are unable to undergo potentially life-saving induction chemotherapy because of the profound anemia the chemotherapy causes. The purpose of the proposed study would be to study the efficacy of Hemopure in delivering oxygen in the absence of red blood cell transfusion. An effective treatment for this patient population represents an unmet medical need because of an expected 100% mortality within several months without induction chemotherapy.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the Company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is developing Hemopure and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold more than 200,000 units of Oxyglobin since its launch.
Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that any proposed trial will be permitted to proceed by the FDA, that if a trial is permitted to proceed funding for the trial will be available or that if a trial is undertaken the results will be as expected. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to resume full operations and remain in business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on September 15, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.
CONTACT: Rob Skiba
Biopure Corporation
(617) 234-6500
IR@biopure.com
I need to sell this POS stock before the end of the year. I've been holding this for about 6 years or so. For me to break-even, this stock has to go up to $120. That will never happen. I really don't see this company surviving much longer.
http://investor.biopure.com/phoenix.zhtml?c=114417&p=irol-SECText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9NTg4NDU1MSZhdHRhY2g9T04%3d
This is the only real news lately -- a Form 4. LOL. Well, I guess...
Sorry about being quiet, but NOTHING is going on. So... dunno what to tell ya guys... Play the chart. Right now, wait -- chart is trying not to go too ugly.
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
347
|
Created
|
10/02/00
|
Type
|
Free
|
Moderators |
Outstanding Shares: 39,709,015 Shares.
Authorized Shares: 200,000,000 Shares.
Number Of Shareholders: 870.
Company Status: In CH11 process, no liquidation value.
Important Websites
Home Page: http://www.biopure.com/
Investor Kit: http://www.biopure.com/corporate/reports/bpur_ekit.zip
Corporate Contact
Biopure Corporation
11 Hurley Street
Cambridge, MA 02141
Phone 617-234-6500
Fax 617-234-6505
About Biopure Corporation (Nasdaq: BPUR)
Biopure Corporation develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. Using our patented and proprietary technology, we have developed and manufacture two products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use, and Oxyglobin® (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use. Hemopure is being sold in South Africa for the treatment of adult surgical patients who are acutely anemic and for eliminating, reducing or delaying the need for allogenic red blood cell transfusion in these patients. A marketing authorization application for Hemopure is pending in the United Kingdom, also for a surgery indication.
We have been developing Hemopure for the treatment of patients with cardiovascular ischemia and supporting the U.S. Navy's government-funded development of the product for out-of-hospital treatment of trauma patients in hemorrhagic shock. To exploit the body of preclinical and clinical information we have involving anemia, we are now beginning development for use of Hemopure in anemic cancer patients and end-of-life patients.
Oxyglobin, our veterinary product for the treatment of anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission. We have sold approximately 200,000 units of Oxyglobin.
We are headquartered and operate a cGMP manufacturing facility in Cambridge, Massachusetts.
Products
Oxygen Bridge
The purpose of intravenous oxygen-delivery support is to help stabilize the patient and prevent tissue damage or organ dysfunction associated with oxygen deprivation. When Hemopure or Oxyglobin is infused into the bloodstream, its chemically stabilized hemoglobin molecules both carry oxygen in the plasma (the fluid part of blood) and facilitate the release of oxygen from red blood cells, thereby increasing diffusion of oxygen to tissues. If necessary, this effect can be extended over time by repeat dosing to provide a continuous Oxygen Bridge until anemic or ischemic patients receive other appropriate therapy.
Hemopure South Africa
HBOC-201 [hemoglobin glutamer - 250 (bovine)]
Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)], is a first-in-class product for human use and approved in South Africa for the treatment of acutely anemic adult surgical patients. Its purpose is to eliminate, reduce or delay these patients' need for allogenic red blood cell transfusions.
Current list: http://www.biopure.com/technology_and_products.php
Biopure Corporation Management
Zafiris G. Zafirelis
Chairman, President and Chief Executive Officer
Zafiris G. Zafirelis has been President, Chief Executive Officer and a director of Biopure since June 2004. In January 2006 he was appointed Chairman of the Board. Before coming to Biopure, he was CEO and a director of MedQuest Product, Inc, Salt Lake City, UT, a pioneering developer of implantable ventricular assist devices. He previously served as CEO and a director of CardiacAssist, Inc., Pittsburgh, PA, and, for four years prior to Biopure's initial public offering, as Director of Product Applications at Biopure. He holds a graduate diploma in chemistry from the University of Rhodesia and an M.B.A. from the University of Southern California.
David A. Butler
Interim Chief Financial Officer
Mr. Butler most recently served as Vice President, Finance and Administration at the Millard Group, Inc., a services & consulting company. Prior to that position, he served as Vice President, Finance, Chief Financial Officer and Treasurer at Circe Biomedical, Inc., a development-stage medical device manufacturer, formerly in Lexington, Mass.
Jane Kober
Senior Vice President, General Counsel and Secretary
Jane Kober has been Senior Vice President, General Counsel and Secretary of Biopure since 1998. From June 1989 to April 1998, she was a partner in LeBoeuf, Lamb, Greene & MacRae, L.L.P. Ms. Kober holds a J.D. degree from Case Western Reserve University, an M.A. degree from the University of Chicago and a B.A. in English from the Pennsylvania State University. She serves as a director of HTV Industries, Inc.
Geoffrey J. Filbey
Vice President, Engineering
Geoffrey J. Filbey joined Biopure in 1985 and has served as Vice President, Engineering since 1995. He previously worked at Stone & Webster Engineering Corporation for 14 years as a project manager and process engineer. Prior to Stone & Webster, he was a plant manager for eight years at Morganite Carbon Co. in London. Mr. Filbey holds a B.Sc. degree in engineering from the City University in London, England.
A. Gerson Greenburg
Vice President, Medical Affairs
A. Gerson Greenburg, M.D., Ph.D. joined Biopure as Vice President, Medical Affairs, in May 2006. He is a board-certified general surgeon and expert in oxygen therapeutics with over 40 years of experience in clinical care, quality systems, teaching and research. A professor emeritus of surgery at Brown University School of Medicine in Providence, R.I., Dr. Greenburg retired from The Miriam Hospital in April 2006 after serving as chief of clinical quality management since 2003 and as surgeon-in-chief from 1986 to 2005. In 2005, he received the hospital's Charles C.J. Carpenter Outstanding Physician of the Year Award. Previously, he was chief of general surgery and surgical intensive care at the Veterans Administration Medical Center in San Diego, Calif., and was a professor of surgery at the University of California, San Diego.
W. Richard Light
Vice President, Technology Development
W. Richard Light, Ph.D., rejoined Biopure as Vice President, Technology Development, in February 2005. During the previous year, Dr. Light was Vice President, Development, at Aeris Therapeutics in Woburn, Mass. He originally joined Biopure in 1990 and has held several positions, including Vice President, Process Technology; Director, Product Development; and Associate Director, Analytical and Protein Chemistry. Dr. Light previously served as a research biochemist and postdoctoral fellow at the Naval Research Laboratory in Washington, D.C. He holds a Ph.D. in biochemistry from Rice University, and has a B.S. in biology and a B.A. in chemistry from Washington & Lee University.
Virginia T. Rentko
Vice President, Preclinical Development
Virginia T. Rentko, V.M.D. is Vice President, Preclinical Development, at Biopure. She is board certified in internal medicine and is an adjunct clinical assistant professor in the Department of Clinical Sciences at Tufts University School of Veterinary Medicine. Dr. Rentko received her V.M.D. degree from the University of Pennsylvania and completed clinical training at the University of Pennsylvania and Tufts University. She obtained her M.S. degree in Zoology at the Ohio State University and her B.S. degree in Biology at Boston University. She is a diplomate of the American College of Veterinary Internal Medicine, and is an active member of the Association of Veterinary Hematology and Transfusion Medicine and the American Veterinary Medical Association.
Barry L. Scott
Vice President, Business Development
Barry L. Scott has been Vice President, Business Development, since September 2003. He joined the company in June 2002 as Vice President, International Business Development. From 1998 until 2002 Mr. Scott worked for Bristol-Myers Squibb Company, most recently as Vice President, International Business Development, Europe. From 1996 until 1998 he was the general manager of Bristol-Myers Squibb, Ltd., South Africa. He also held several positions, including Director of Marketing and Sales, during his 20 years at Merck Sharp and Dhome, the South Africa subsidiary of Merck & Co. Mr. Scott holds the Diploma in Education from the University of Rhodesia and the Diploma in Marketing Management from the Institute of Marketing Management, South Africa.
Filings and Other Information
http://sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000815508&owner=include&count=40
News
http://investor.biopure.com/phoenix.zhtml?c=114417&p=irol-news&nyo=0
Chart and Stock Information
Share Structure
O/S: 33,918,000
Ref: http://investor.biopure.com/phoenix.zhtml?c=114417&p=IROL-secToc&TOC=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvY29udGVudHMueG1sP2lwYWdlPTU1MzkzMjYmcmVwbz10ZW5r
American Stock Transfer & Trust Co.
Shareholder Services
59 Maiden Lane, Plaza Level
New York, NY 10038
Phone: 800-937-5449
Fax: 718-236-2641
Charts
_______________________________________
Updated 16 MAY 2008 by Soapy Bubbles
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |